Introduction {#s1}
============

Methamphetamine (METH) is an indirect agonist that induces the release of dopamine (DA) in brain regions that receive projections from the substantia nigra pars compacta and the ventral tegmental area [@pone.0084665-Bustamante1]--[@pone.0084665-Xi1]. These brain regions include the nucleus accumbens and the dorsal striatum. METH administration also influences striatal gene expression in animals with normal dopaminergic innervation [@pone.0084665-Cadet1]--[@pone.0084665-Jayanthi1]. The METH-induced transcriptional changes in the dorsal striatum include increases in the expression of various immediate early genes (IEGs) including *c-fos* and *Egr* families of transcription factors, neuropeptides including neurotensin, and genes that participate in either toxic or protective cascades such as heat shock proteins and genes involved in endoplasmic reticulum stress, depending on the doses of METH used [@pone.0084665-Cadet2]--[@pone.0084665-Thomas1]. We have shown, in addition, that some of these changes can be attenuated by DA receptor antagonism [@pone.0084665-Jayanthi1]--[@pone.0084665-Jayanthi2] or repeated METH injections [@pone.0084665-Cadet2]. Nevertheless, these studies had only included very short-term biochemical or transcriptional effects of the drug and focused mainly on the dorsal striatum. Moreover, although the acute changes in METH-induced gene expression [@pone.0084665-Cadet3] and the toxic effects of the drug [@pone.0084665-Jayanthi1], [@pone.0084665-Jayanthi2], [@pone.0084665-Krasnova1] have been extensively investigated in the dorsal striatum, very few papers have reported on the potential long-term behavioral and/or biochemical effects of a single injection of moderate doses of the drug. For example, Xi et al. [@pone.0084665-Xi1] have shown that a single METH (10 or 20 mg/kg) injection can increase cocaine self-administration measured several days after the METH injection, thus documenting long-term behavioral effects of the drug. They showed that these METH doses also impacted the biochemical effects of cocaine in the nucleus accumbens [@pone.0084665-Xi1]. More recently, Martin et al. [@pone.0084665-Martin1] investigated the biochemical and molecular effects of a single METH (20 mg/kg) injection and identified substantial time-dependent changes in gene expression, histone acetylation, and expression of histone deacetylases (HDACs) in the NAc. We are, however, not aware of any study that has investigated the molecular effects of re-exposing rats to METH after a long period of abstinence following the injection of a single moderate but nonlethal dose of the drug. Moreover, to our knowledge, there is no study of the long-term effects of single or multiple exposures to the drug on global gene expression in the rat NAc, given the importance of that structure in reward mechanisms [@pone.0084665-Willuhn1], [@pone.0084665-Wise1].

Repeated injections of psychostimulant are the most often used model to examine the long-term effects of these drugs [@pone.0084665-Steketee1]. These studies have reported substantial activation of the mesolimbic dopaminergic projections [@pone.0084665-Cornish1]. However, there is evidence that even a single dose exposure can cause long-term alterations in dopaminergic systems, neuroendocrine, and physiological effects in rodents [@pone.0084665-Keller1]--[@pone.0084665-Vanderschuren1]. Specifically, Peris and Zahniser [@pone.0084665-Peris1] showed that a single injection of cocaine caused potentiation of amphetamine-induced DA release from rat striatal slices. In rats, a single prior cocaine injection augmented a second cocaine injection-induced striatal DA release measured one week later [@pone.0084665-Keller1]. Vanderschuren et al. [@pone.0084665-Vanderschuren1] showed that the injection of a larger dose of amphetamine (5 mg/kg) injection also potentiated the biochemical effects of the injection of a second smaller dose of amphetamine (1 mg/kg) given 3 weeks later. Thus, when taken together with the behavioral and biochemical effects reported after a single METH pre-exposure [@pone.0084665-Xi1], the possibility existed that a single METH injection might cause long-term biochemical and molecular changes in the rat NAc. We also tested the idea that such a moderate dose of METH might potentiate the molecular effects of the injection of a second lower dose of the drug in a fashion previously reported after a similar pattern of amphetamine injections [@pone.0084665-Vanderschuren1]. In order to address these questions further, we used a two-dose METH exposure paradigm similar to that used by Vanderschuren et al. [@pone.0084665-Vanderschuren1] to measure the effects of METH on gene expression in the NAc by using both microarray and quantitative PCR analyses. Thus, the purpose of the present paper was three fold. First, we sought to determine the acute effects of a single METH dose (2.5 mg/kg) on global gene expression in the NAc. We have previously shown that similar doses of METH can cause substantial changes in gene expression in the dorsal striatum [@pone.0084665-Cadet1], [@pone.0084665-McCoy1] but, to our knowledge, there are no similar data on the effects of similar doses of METH on global gene expression in the NAc. The second purpose of the study was to investigate the long-term effects of a moderate METH dose (10 mg/kg) in that brain structure. The studies that have investigated the effects of larger doses of METH (20--40 mg/kg) have reported on relatively short-term transcriptional effects of the drug on the cortex [@pone.0084665-Jayanthi1], [@pone.0084665-Thomas1], [@pone.0084665-Cadet4]. This issue is also important because we have shown that a single moderate dose of the drug can have long-term behavioral and biochemical effects [@pone.0084665-Xi1], [@pone.0084665-Sabol1], results that suggest the possibility of long-lasting transcriptional effects of the drug. The third aim of the paper was to test if the single moderate dose of the drug could influence the transcriptional effects of a lower dose of the drug given one month later. We and others have reported that repeated injections of METH can attenuate the IEG [@pone.0084665-Cadet2], [@pone.0084665-McCoy1], toxic [@pone.0084665-Danaceau1], and biochemical [@pone.0084665-Segal1] responses to either smaller or larger doses given within a few hours after the end of the repeated METH injections. Frankel et al. [@pone.0084665-Frankel1] had also reported that a prior injection of a larger METH dose caused a potentiated locomotor response to a lower dose of the drug. Taken together, the literature suggests prior exposure to METH can influence subsequent exposure to a lower dose of the drug. However, we are not aware of any studies that have measured acute METH-induced changes in gene expression in the NAc after a long delay from an initial METH exposure. The present study was meant, in part, to fill that gap. These types of studies might be relevant to the effects of the drug on the brains of patients who go back to using drugs after long periods of abstinence.

In addition to measuring global gene expression, we used Ingenuity Pathway Analysis (IPA) to identify networks and canonical pathways that might be perturbed after injections of the drug. Our study reveals that a moderate dose of METH (10 mg/kg) can cause long-lasting changes in the mRNA expression of several neuropeptides including CRF, CART, AVP, and OXT in the NAc. Moreover, we showed that a prior exposure to METH (10 mg/kg) significantly influenced the acute transcriptional effects of a second delayed smaller dose of the drug (2.5 mg/kg) injection. These results are discussed in view of their support for the potential involvement of these neuropeptides in the psychostimulant-induced molecular neuroadaptations in the NAc.

Results {#s2}
=======

Monoamine levels in the NAc {#s2a}
---------------------------

In order to investigate the effects of METH pretreatment, we performed HPLC analyses in four experimental groups: saline-pretreated and saline-challenged (SS) (n = 4); saline-pretreated and METH-challenged (SM) (n = 8); METH-pretreated and saline-challenged (MS) (n = 9); and METH-pretreated and METH-challenged (MM) (n = 9). [Table 1](#pone-0084665-t001){ref-type="table"} shows the effects of METH on monoamine levels in the NAc of these rats. There were no significant differences in DA and 3, 4-dihydroxyphenylacetic acid (DOPAC) between the SS and MS groups. There were non-significant increases (+63%, *P* = 0.076) in homovanillic acid (HVA) levels in the MS in comparison to the SS group. The acute METH injection caused significant increases in DA and HVA levels in the saline- (SM) (+31.6% and +75%, respectively) and METH-pretreated (MM) (+40.8% and +98%, respectively) groups in comparison to the SS group. In addition, DA levels were significantly higher in the MM (+24.5%) in comparison to the MS group. There were no significant differences in DA, DOPAC, or HVA levels between the SM and MM groups. Serotonin (5-HT) and 5-hydroxyindole acetic acid (5-HIAA) levels were not significantly affected by any of the METH treatments.

10.1371/journal.pone.0084665.t001

###### Effects of METH on monoamine levels in the NAc.

![](pone.0084665.t001){#pone-0084665-t001-1}

  Amines       SS                          SM                          MS                                             MM
  -------- ----------- ------------------------------------------- ----------- --------------------------------------------------------------------------------
  DA        6.67+0.95   8.78+0.51[a](#nt102){ref-type="table-fn"}   7.54+0.90   9.39+0.55[b](#nt103){ref-type="table-fn"} ^,^ [c](#nt104){ref-type="table-fn"}
  DOPAC     1.27+0.19                   1.37+0.07                   1.44+0.10                                     1.54+0.55
  HVA       0.58+0.17   1.02+0.11[a](#nt102){ref-type="table-fn"}   0.94+0.10                     1.15+0.13[b](#nt103){ref-type="table-fn"}
  5-HT      1.18+0.13                   1.20+0.11                   1.17+0.10                                     1.16+0.08
  5-HIAA    0.84+0.08                   0.95+0.08                   0.90+0.09                                     0.97+0.08

The values represent means + SEM (ng/mg tissue) per group saline-pretreated and saline-challenged (SS) (n = 4); saline-pretreated and METH-challenged (SM) (n = 8); METH-pretreated and saline-challenged (MS) (n = 9); and METH-pretreated and METH-challenged (MM) (n = 9).

p\<0.05;

p\<0.01 in comparison to the SS group;

p\<0.05 in comparison to the MS group.

No significant differences were observed between the SM and MM groups.

Microarray analyses in the NAc {#s2b}
------------------------------

In order to identify genes that are different between the four experimental groups (4 rats in SS; 6 rats in SM; and 7 rats in each MS and MM groups, see Table S1 in [File S1](#pone.0084665.s001){ref-type="supplementary-material"}), we performed microarray analyses using Rat Illumina arrays that contain 22,523 probes. The microarray data have been deposited in the NCBI database: GEO accession number GSE46717. We used a cut-off of 1.8-fold changes at *P*\<0.01 because we have been able to replicate the changes in transcript levels by quantitative PCR analysis after identifying genes with similar criteria [@pone.0084665-Cadet2], [@pone.0084665-Jayanthi1], [@pone.0084665-Martin1]. [Figure 1](#pone-0084665-g001){ref-type="fig"} is a Venn diagram showing the effects of METH in four sets of comparison. Injection of METH (2.5 mg/kg) caused differential changes in the expression of a total of 412 transcripts (352 up-, 60 down-regulated) (SMvSS comparison). Injection of the larger METH (10 mg/kg) dose caused changes in the expression of 503 (338 upregulated, 165 down-regulated) transcripts in rats euthanized one month later (MSvSS comparison). Injection of METH (2.5 mg/kg) caused significant changes in 766 (565 upregulated, 201 down-regulated) transcripts in animals previously treated with a METH (10 mg/kg) injection one month earlier (MMvSS comparison). The single METH injection altered the expression of 130 transcripts (89 upregulated, 41 down-regulated) in animals previously treated with the METH (10 mg/kg) one month previously when compared to METH-pretreated rats challenged with saline (MMvMS comparison). There was a substantial degree of overlap in the identity of genes differentially expressed in the SMvSS and MSvSS comparisons, with 221 genes coexisting between these two comparisons. There were 344 genes located in the overlap between the MSvSS and the MMvSS comparisons while 265 genes were found in the overlap between the SMvSS and MMvSS comparisons. Interestingly, 201 genes were found in the SMvSS, MSvSS, and MMvSS comparisons, suggesting that the expression of many genes affected acutely by METH remained significantly altered for a period of, at least, one month after the injection.

![A single injection of METH (10 mg/kg) caused long-lasting changes in gene expression in the rat nucleus accumbens.\
The Venn diagram shows the overlap of genes in the four comparisons described in the text: SMvSS, MSvSS, MMvSS, and MMvMS. The rats were treated as described in the text and the animals were euthanized 2 hours after the second injection of either saline or METH. The microarray experiments were performed as described in the method section. Genes were identified as differentially expressed if they showed greater than+1.8-fold changes at *P*\<0.01, using the GeneSpring statistical package.](pone.0084665.g001){#pone-0084665-g001}

[Table 2](#pone-0084665-t002){ref-type="table"} shows a partial list and the classes of genes that are up-regulated in comparison. to the SS group. Genes with increased expression in SMvSS include *Avp* (∼26.5-fold); *Cart* (7.6-fold); *Nr4a3* (5.85-fold); *c-fos* (5.25-fold); *Crf/Crh* (5.06-fold) and *Sst* (1.87-fold). The abbreviations are listed in the table. The METH-induced changes in immediate early genes (IEGs) are consistent with our previous observations that single or multiple injections of the drug can cause significant increases in striatal IEG expression [@pone.0084665-Cadet1]--[@pone.0084665-Jayanthi1], [@pone.0084665-Jayanthi2]. Pathway analysis using the IPA program identified several networks in which the METH-regulated genes participate. These include cell signaling, cell-to-cell signaling and interaction, nervous system development, and endocrine system functions. Top canonical pathways include G-Protein-coupled receptor signaling. [Figure 2](#pone-0084665-g002){ref-type="fig"} shows a network that contains genes that are involved in cell signaling, CRH signaling and other endocrine functions. The activation of these endocrine signaling pathways after METH supports the suggestions that various peptide neurotransmitters might be involved in both the acute and long-term effects of drugs of abuse [@pone.0084665-Boutrel1], [@pone.0084665-Koob1] see discussion below). [Figure 2](#pone-0084665-g002){ref-type="fig"} also provides evidence of METH induced regulation of genes connected to transcription regulation. These observations are consistent with those reported by several groups of investigators who had performed microarray analyses in forebrain dopaminergic projection areas of rodent brains [@pone.0084665-Cadet3]--[@pone.0084665-Thomas1], [@pone.0084665-Martin1], [@pone.0084665-Krasnova2]--[@pone.0084665-Yang1].

![An acute METH injection induces changes in a network of genes that participate in cell and CRF signaling.\
The networks of related genes were generated through the use of IPA (Ingenuity® Systems, [www.ingenuity.com](http://www.ingenuity.com)). This figure shows that the relationship of several neuropeptides including Avp, Crh (Crf), and Sst that were significantly induced after the acute METH (2.5 mg/kg) injection. The genes were a subset of genes from the SMvSS comparison shown in [figure 1](#pone-0084665-g001){ref-type="fig"}. Relationships are shown as lines and arrows. The genes colored red to pink are up-regulated whereas those colored deep to light green are down-regulated. The intensity of the color represents is proportional to fold changes. The indirect relations between the genes were shown in dotted arrows and direct interaction in solid arrows. Arrows are colored differently to ease the identification of each connection. The various shapes within the figure represent the functional classes of the specific gene products (see legend in the top left).](pone.0084665.g002){#pone-0084665-g002}

10.1371/journal.pone.0084665.t002

###### Partial list of METH-upregulated genes in comparison to SS group.

![](pone.0084665.t002){#pone-0084665-t002-2}

  Symbol                                                      Definition                          Fold changes              
  ----------------------------------- ---------------------------------------------------------- -------------- ----------- -----------
  *ADP-ribosylation*                                                                                                        
  Art5                                                 ADP-ribosyltransferase 5                       2.36       **4.15**    **3.31**
  *Axon guidance/cell cycle*                                                                                                
  Clasp1                                       cytoplasmic linker associated protein 1                2.25         3.09      **3.15**
  Plxna4                                                      plexin A4                             **2.57**       1.15        2.00
  *Cell adhesion*                                                                                                           
  Cpne4                                                       copine IV                               5.48       **5.88**      8.48
  Lypd3                                             Ly6/Plaur domain containing 3                     3.85       **5.66**    **6.63**
  Mpeg1                                              macrophage expressed gene 1                    **5.52**     **4.27**      4.33
  Parvb                                                      parvin, beta                             2.28         2.41      **3.14**
  Pcdh18                                                   protocadherin 18                           4.99       **5.92**      7.16
  Shank2                                              SH3/ankyrin domain gene 2                       1.02         1.38      **3.54**
  *Cell death*                                                                                                              
  Gpx3                                                 glutathione peroxidase 3                     **2.13**       2.57        2.68
  Nell1                                                  NEL-like 1 (chicken)                         3.90       **3.99**    **4.18**
  Unc5d                                             unc-5 homolog D (*C. elegans*)                    3.81       **5.36**      5.02
  *Cell growth*                                                                                                             
  Fgf11                                              fibroblast growth factor 11                      1.30         2.73      **3.55**
  Igfbp2                                     insulin-like growth factor binding protein 2             1.72         2.17      **4.94**
  *Cell morphogenesis*                                                                                                      
  Gbx2                                              gastrulation brain homeobox 2                     5.07       **18.00**     20.82
  Tnnt2                                                  troponin T2, cardiac                       **5.14**     **4.68**      4.94
  Vax1                                       ventral anterior homeobox containing gene 1              2.41       **3.06**      2.57
  *Defense/Immune systems*                                                                                                  
  Calcr                                                  calcitonin receptor,                      **14.75**     **23.86**   **19.14**
  Ccr1                                             chemokine (C-C motif) receptor 1                   5.27       **4.18**      4.77
  Cxcl13                                          chemokine (C-X-C motif) ligand 13                   8.57       **11.49**   **12.93**
  Defb1                                                    defensin beta 1                            6.62       **8.56**    **11.20**
  Il2                                                       interleukin 2                           **7.02**     **4.67**    **5.03**
  *Development*                                                                                                             
  Aard                                   alanine and arginine rich domain containing protein          6.87       **8.40**      9.50
  Chrd                                                         chordin                                3.46       **3.83**      2.72
  Dlk1                                           delta-like 1 homolog (*Drosophila*)                  6.87       **6.00**      5.74
  Myh6                                    myosin, heavy polypeptide 6, cardiac muscle, alpha          2.42         2.81      **3.16**
  Otx2                                          orthodenticle homolog 2 (*Drosophila*)                4.77       **4.75**      6.28
  Rtbnd                                                       retbindin                               5.91       **6.30**    **4.93**
  Susd3                                               sushi domain containing 3                       3.90       **5.91**      3.61
  *Homeostasis*                                                                                                             
  Pmch                                            pro-melanin-concentrating hormone                  15.83       **19.36**   **28.83**
  Rxfp3                                           relaxin family peptide receptor 3                   9.78       **9.32**      13.14
  Tfrc                                                   transferrin receptor                         4.80         5.28      **5.55**
  Agtr1a                                           angiotensin II receptor, type 1                    2.17       **5.19**      6.66
  Cckar                                               cholecystokinin A receptor                      3.95       **6.58**      8.91
  Cidea                                      cell death-inducing DNA fragmentation factor             1.65       **4.40**      3.10
  *Intracellular protein transport*                                                                                         
  Rpl30                                                 ribosomal protein L30                         4.34       **5.64**    **7.18**
  Slc7a3                                          solute carrier family 7, member 3                   3.58       **3.90**      3.90
  Stx17                                                      syntaxin 17                            **5.81**       3.55        5.81
  Tmem7                                                transmembrane protein 7                      **3.65**     **4.05**    **3.26**
  Vamp1                                         vesicle-associated membrane protein 1               **2.18**       2.03        2.50
  *Ion transport*                                                                                                           
  Cacna2d2                                        calcium channel, voltage-dependent                 21.16         10.84     **3.59**
  Clcn1                                                   chloride channel 1                        **1.90**       1.62        1.41
  Fstl5                                                   follistatin-like 5                          3.28         3.32      **3.39**
  Gabra1                                     gamma-aminobutyric acid A receptor, alpha 1              3.35       **3.02**      4.79
  Kcnc2                                            potassium voltage gated channel                  **2.11**       2.00        2.12
  Kcnj16                                        potassium inwardly-rectifying channel               **8.07**     **9.00**    **12.98**
  Kcns3                                   potassium voltage-gated channel, delayed-rectifier        **2.68**       2.63        2.69
  *Metabolic process*                                                                                                       
  Cdk10                                               cyclin-dependent kinase 10                    **2.07**       1.78        1.75
  Gdpd2                                     glycerophosphodiester phosphodiesterase domain            3.22       **4.77**      4.08
  Ptpn18                                  protein tyrosine phosphatase, non-receptor type 18        **5.81**       3.30        4.28
  *Neuropeptides/Hormone activity*                                                                                          
  Avp                                                    arginine vasopressin                      **26.47**       10.84     **15.99**
  Avpr1a                                           arginine vasopressin receptor 1A                 **8.57**     **8.12**    **9.27**
  Cart                                       cocaine and amphetamine regulated transcript           **7.63**     **5.65**    **4.97**
  Crh                                              corticotropin releasing hormone                  **5.06**     **4.00**    **7.33**
  Gast                                                         gastrin                              **5.46**       5.01      **4.88**
  Gnrh1                                            gonadotropin-releasing hormone 1                 **4.01**     **3.56**    **4.45**
  Nts                                                        neurotensin                            **2.09**       1.68        1.83
  Oxt                                                          oxytocin                              11.50         7.98      **14.91**
  Sst                                                        somatostatin                           **1.87**       1.58        1.73
  Sstr1                                                somatostatin receptor 1                      **2.98**     **3.27**    **3.97**
  *Regulation of neurotransmitter*                                                                                          
  Chat                                                choline acetyltransferase                       1.71         2.44      **3.04**
  *Regulation of nucleotide*                                                                                                
  Adcy7                                                  adenylate cyclase 7                          2.54       **4.12**    **4.82**
  Adcy8                                                  adenylate cyclase 8                        **2.30**       2.33        2.35
  *Sensory perception*                                                                                                      
  Otog                                                         otogelin                             **4.43**       1.22        1.79
  *Signal transduction*                                                                                                     
  Arc                                     activity regulated cytoskeletal-associated protein        **2.17**       -1.30       1.66
  Calb2                                                      calbindin 2                              5.41       **6.09**    **6.01**
  Camk1g                                 calcium/calmodulin-dependent protein kinase I gamma        **2.46**       1.91        2.48
  Camk2d                                calcium/calmodulin-dependent protein kinase II, delta       **2.71**       2.15        2.36
  Cyp26a1                               cytochrome P450, family 26, subfamily a, polypeptide 1        4.21         2.70      **3.71**
  Disp2                                                  dispatched homolog 2                         2.64         3.38      **3.42**
  Dusp5                                             dual specificity phosphatase 5                  **2.43**       1.05        1.63
  Gdap1l1                              ganglioside-induced differentiation-associated protein 1     **1.84**       1.72        1.62
  Gpr103                                            G protein-coupled receptor 103                 **20.41**     **24.36**   **29.26**
  Hap1                                             huntingtin-associated protein 1                  **3.33**     **3.29**    **4.40**
  Hcrtr2                                                hypocretin receptor 2                         2.75         2.70      **3.08**
  Ifitm6                                      interferon induced transmembrane protein 6            **2.16**       1.60        1.48
  Insr                                                     insulin receptor                           2.33         2.61      **5.03**
  Klhl12                                             kelch-like 12 (*Drosophila*)                   **2.30**       1.89        1.91
  Myo16                                                       myosin XVI                            **3.19**       3.33      **3.22**
  Nmbr                                                  neuromedin B receptor                       **4.44**       2.78        3.93
  Nnat                                                        neuronatin                            **5.85**     **5.09**    **5.25**
  Nrip3                                         nuclear receptor interacting protein 3                2.20         2.58      **3.11**
  Peli1                                            pellino homolog 1 (*Drosophila*)                **28.74**     **7.31**    **19.77**
  Pnoc                                                     prepronociceptin                         **2.05**       1.97        2.08
  Pth2r                                             parathyroid hormone 2 receptor                    7.78       **11.84**     13.31
  Stap2                                       signal transducing adaptor family member 2              2.96       **3.38**      2.70
  Slc17a6                                         solute carrier family 17, member 6                  4.66       **5.87**      6.45
  Htr7                                              5-hydroxytryptamine receptor 7                    3.03       **3.26**      3.31
  *Structural*                                                                                                              
  Myom3                                               myomesin family, member 3                     **7.83**     **4.18**    **6.13**
  Nup133                                                   nucleoporin 133                            1.32         1.93      **3.56**
  Cbln2                                             cerebellin 2 precursor protein                    1.94       **3.56**    **4.50**
  *Transcription*                                                                                                           
  Crebl2                                    cAMP responsive element binding protein-like 2          **2.69**       1.69        2.08
  Egr2                                                 early growth response 2                      **2.68**       1.12        1.60
  Egr4                                                 early growth response 4                      **3.24**       1.04        1.93
  Fos                                       FBJ murine osteosarcoma viral oncogene homolog          **5.25**       1.35      **5.27**
  Hsf4                                            heat shock transcription factor 4                   2.63       **3.16**    **3.25**
  Junb                                                      Jun-B oncogene                          **2.88**       1.24        2.12
  Nkx2-5                                      NK2 transcription factor related, locus 5               2.24         1.69      **3.52**
  Npas4                                             neuronal PAS domain protein 4                     4.96         1.44      **5.08**
  Nr4a3                                    nuclear receptor subfamily 4, group A, member 3          **5.85**       1.38      **3.94**
  *Urea cycle*                                                                                                              
  Arg2                                                        arginase 2                            **2.31**       1.98        2.15

The animals were treated and microarray analyses were performed as described in the text. The number listed in bold under the representative columns (SMvSS, MSvSS, MMvSS) identify genes whose mRNA were significantly increased according to the following criteria: greater than +1.8-fold, p\<0.01. In some cases, values that are greater than 1.8-fold are not in bold because they did not reach the p value cut-off for the microarray analysis.

[Table 2](#pone-0084665-t002){ref-type="table"} also shows a list of genes that were differentially expressed one month after a single injection of METH (10 mg/kg) (MSvSS comparison). The list includes *Cckar* (cholecystokinin A receptor) (6.58-fold), *Cart* (5.65-fold), *Crh* (4-fold), and *Gnrh1* (3.56-fold) that showed increased mRNA levels. Interestingly, there was METH-induced down-regulation of *Cck* (−3.43-fold) in that group (see [Table 3](#pone-0084665-t003){ref-type="table"} and [Fig. 3A](#pone-0084665-g003){ref-type="fig"}). Of interest is the fact that, in the MS group, there were no increases in the expression of any IEGs that were affected in the SM group. The present observations are consistent with those of a previous report that the induced IEG expression caused by METH (20 mg/kg) had reverted to normal by 16 hours after the drug injection [@pone.0084665-Martin1]. IPA revealed that the genes whose expression was affected by the METH injection participated in cell death mechanisms, inflammatory responses, and endocrine functions. The activation of genes involved in death mechanisms and in inflammatory responses is consistent with previous data that have shown that METH can cause neurodegenerative changes [@pone.0084665-Jayanthi2], [@pone.0084665-Krasnova1] and increased expression of neuroinflammatory markers [@pone.0084665-Clark1], [@pone.0084665-Kelly1]. Canonical pathways of interest also included cAMP-mediated signaling, CRH signaling, and genes that are involved in the regulation of synaptic long-term potentiation. These observations are consistent with the fact that psychostimulant can cause prolonged changes in synaptic plasticity [@pone.0084665-Ungless1], [@pone.0084665-Mameli1]. IPA also identified networks of genes that are involved in cellular growth and proliferation ([Fig. 3A](#pone-0084665-g003){ref-type="fig"}) and in endocrine system disorders ([Fig. 3B](#pone-0084665-g003){ref-type="fig"}). The potential involvement of these genes and pathways in the acute and chronic effects of psychostimulant is discussed below (see also [@pone.0084665-Koob1], [@pone.0084665-Kuhar1]).

![A METH (10 mg/kg) injection caused delayed changes in a network of genes involved in (A) cellular growth and proliferation and (B) in endocrine system regulation.\
This network of related genes was generated as described in [figure 2](#pone-0084665-g002){ref-type="fig"}. Relationships between genes are also described in [figure 2](#pone-0084665-g002){ref-type="fig"}. The rats were injected with METH (10 mg/kg) and were euthanized 2 hours after an injection of saline one month later. The genes were from the MSvSS comparison shown in [figure 1](#pone-0084665-g001){ref-type="fig"}. Several neuropeptides of interest including Cart and Crh (Crf) are upregulated one month after the single METH injection (**B**). In addition to the many upregulated genes, the [figure 2A](#pone-0084665-g002){ref-type="fig"} also shows that METH caused down-regulation of Cck mRNA one month after its injection.](pone.0084665.g003){#pone-0084665-g003}

10.1371/journal.pone.0084665.t003

###### Partial list of METH down-regulated genes in comparison to SS group.

![](pone.0084665.t003){#pone-0084665-t003-3}

  Symbol                                                                 Definition                                        Fold changes              
  --------------------------------- ------------------------------------------------------------------------------------- -------------- ----------- ------------
  *Cell adhesion*                                                                                                                                    
  Actn1                                                               actinin, alpha 1                                        −1.65         −1.68     **−2.13**
  Actn2                                                                actinin alpha 2                                        −1.44       **−1.84**   **−2.05**
  Ceacam10                                       carcinoembryonic antigen-related cell adhesion molecule 10                 **−2.03**       −1.72       −1.95
  Epor                                                             erythropoietin receptor                                    −1.84       **−2.00**     −2.79
  Ptpn7                                               protein tyrosine phosphatase, non-receptor type 7                       −1.62       **−2.05**   **−2.14**
  Ptprcap                               protein tyrosine phosphatase, receptor type, C polypeptide-associated protein         −1.50         −2.47     **−3.53**
  Ptprv                                                protein tyrosine phosphatase, receptor type, V                       **−2.01**     **−2.12**   **−2.95**
  Sema7a                                                     semaphorin 7A, GPI membrane anchor                             **−2.96**     **−3.16**     −2.77
  *Cell cycle*                                                                                                                                       
  Cdc20                                                            cell division cycle 20                                     −1.31         −1.55     **−1.88**
  Cdc2a                                                 cell division cycle 2 homolog A (*S. pombe*)                          −2.18       **−3.45**   **−4.68**
  Cdca1                                                       cell division cycle associated 1                                −1.25         −1.61     **−1.93**
  Cdca7                                                       cell division cycle associated 7                                −2.03       **−3.48**   **−5.46**
  Cks2                                                    CDC28 protein kinase regulatory subunit 2                           −1.46         −2.20     **−2.58**
  *Cell death*                                                                                                                                       
  Bik                                                   BCL2-interacting killer (apoptosis-inducing)                          −1.85         −2.34     **−2.89**
  Card6                                                  caspase recruitment domain family, member 6                           1.89         −1.27     **−2.45**
  Lcn2                                                                   lipocalin 2                                          −2.58       **−3.08**     −2.06
  Lyzl4                                                                lysozyme-like 4                                        −1.62       **−2.19**   **−2.55**
  Mzb1                                                  marginal zone B and B1 cell-specific protein                          −1.98       **−2.99**   **−2.48**
  Osgin1                                                 oxidative stress induced growth inhibitor 1                          −4.59         −2.90     **−3.57**
  Unc5b                                                                unc-5 homolog B                                        −1.42         −1.37     **−1.90**
  *Cell growth*                                                                                                                                      
  Efemp2                                         EGF containing fibulin-like extracellular matrix protein 2                   −1.51       **−1.83**   **−1.89**
  Rhbdf1                                                              rhomboid family 1                                      **2.27**     **−2.07**     −1.76
  Tgfb1                                                      transforming growth factor, beta 1                               −1.84       **−1.85**   **−1.85**
  *Cell organization*                                                                                                                                
  Acvr1c                                                         activin A receptor, type IC                                  −2.26       **−2.58**   **−2.91**
  Brsk2                                                         BR serine/threonine kinase 2                                  −2.70       **−3.57**   **−3.44**
  Cdc42ep1                                              CDC42 effector protein (Rho GTPase binding) 1                       **−1.91**       −1.38     **−1.90**
  Cenpe                                                             centromere protein E                                      −2.95         −2.64     **−3.84**
  Dscc1                                               defective in sister chromatid cohesion 1 homolog                        −1.32         −1.60     **−2.45**
  Kif11                                                           kinesin family member 11                                    −2.70         −2.60     **−5.78**
  Kif23                                                           kinesin family member 23                                    −1.40         −1.73     **−2.29**
  Kif4                                                             kinesin family member 4                                    −3.70       **−7.04**     −3.43
  Kifc1                                                           kinesin family member C1                                    −2.34       **−1.93**    **2.02**
  Mcm3                                                 minichromosome maintenance complex component 3                         −2.56       **−3.96**    **3.96**
  Myh7b                                                 myosin, heavy chain 7B, cardiac muscle, beta                          −1.26         −1.94     **−2.93**
  P2ry2                                                 purinergic receptor P2Y, G-protein coupled, 2                       **−3.05**       −1.95       −2.88
  Pde10a                                                            phosphodiesterase 10A                                     −1.55       **−2.03**   **−1.82**
  Plk1                                                        polo-like kinase 1 (*Drosophila*)                             **−1.94**     **−2.70**   **−4.36**
  Rsb66                                                                Rsb-66 protein                                         −1.28         −1.27     **−2.15**
  Hs3st2                                            heparan sulfate (glucosamine) 3-O-sulfotransferase 2                      −1.58       **−2.56**     −2.16
  *Cytoskeleton*                                                                                                                                     
  Gypc                                                                  glycophorin C                                         −1.20       **−2.74**   **−2.75**
  Krt17                                                                  keratin 17                                         **−2.15**     **−2.30**   **−2.86**
  Obsl1                                                                obscurin-like 1                                        −3.23         −2.62     **−4.32**
  Synpo2                                                               Synaptopodin 2                                         −1.33       **−2.13**   **−2.28**
  Tnnt1                                                          troponin T1, skeletal, slow                                  −1.52       **−2.42**   **−3.18**
  *Defense/Immune response*                                                                                                                          
  Clcf1                                                     cardiotrophin-like cytokine factor 1                              −9.10       **−8.82**     −6.64
  Cxcl11                                                      chemokine (C-X-C motif) ligand 11                               −4.22       **−4.21**   **−4.34**
  Dmkn                                                                    dermokine                                         **−2.86**     **−2.86**   **−4.52**
  Igsf9                                                     immunoglobulin superfamily, member 9                              −1.79       **−1.89**   **−2.33**
  Il17re                                                          interleukin 17 receptor E                                   −2.59       **−2.87**     −2.44
  Irf6                                                         interferon regulatory factor 6                               **−3.06**     **−4.99**   **−4.63**
  Itk                                                            IL2-inducible T-cell kinase                                  −1.96         −1.79     **−2.91**
  Mill1                                                            MHC I like leukocyte 1                                     −1.25         −1.31     **−3.13**
  Pik3cd                                   phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit delta          **−2.30**     **−2.77**   **−2.76**
  Pirb                                                            paired-Ig-like receptor B                                   −1.50       **−2.90**     −1.96
  Ptges                                                           prostaglandin E synthase                                  **−3.19**     **−3.19**   **−2.91**
  *Development*                                                                                                                                      
  Adm                                                                  adrenomedullin                                       **−2.16**       −2.08       −1.30
  Angpt2                                                               angiopoietin 2                                       **−2.54**     **−3.03**   **−3.47**
  Ascl1                                                     achaete-scute complex homolog-like 1                            **−1.64**     **−1.91**   **−2.13**
  Cdr2                                                        cerebellar degeneration-related 2                             **−1.90**     **−2.44**   **−1.82**
  Coch                                                                     cochlin                                            −1.81       **−2.23**   **−2.52**
  Col18a1                                                     procollagen, type XVIII, alpha 1                                −1.77       **−2.13**   **−2.24**
  Cryab                                                              crystallin, alpha B                                    **−1.91**     **−2.21**     −1.69
  Gfap                                                         glial fibrillary acidic protein                              **−2.75**     **−2.35**   **−2.22**
  Plg                                                                    plasminogen                                        **−10.09**    **14.35**   **−16.06**
  Slit3                                                         slit homolog 3 (*Drosophila*)                               **−1.93**     **−2.74**   **−2.68**
  Zc3h12a                                                   zinc finger CCCH type containing 12A                            **−3.86**       −3.44       −1.68
  *DNA repair*                                                                                                                                       
  Ddit4l                                                   DNA-damage-inducible transcript 4-like                             −3.69         −4.39     **−5.63**
  Mdc1                                                       mediator of DNA-damage checkpoint 1                               1.07         −1.01     **−1.89**
  *Electron transport*                                                                                                                               
  Cyp4b1                                            cytochrome P450, family 4, subfamily b, polypeptide 1                     −3.71         −2.68     **−3.25**
  *Homeostasis*                                                                                                                                      
  Ptchd2                                                         patched domain containing 2                                  −1.84       **−2.00**   **−2.11**
  *Ion binding*                                                                                                                                      
  Arid5a                                                        AT rich interactive domain 5A                                 −1.39       **−6.12**      1.23
  Car7                                                              carbonic anhydrase 7                                    **−2.04**     **−1.85**   **−2.04**
  *Ion transport*                                                                                                                                    
  Kcng1                                            potassium voltage-gated channel, subfamily G, member 1                     −1.44       **−1.95**     −1.57
  Kcnh7                                                 potassium voltage-gated channel, subfamily H                          −1.81       **−4.29**     −1.15
  Kcns2                                   potassium voltage-gated channel, delayed-rectifier, subfamily S, member 2           −1.50       **−2.10**     −1.62
  Scn4b                                                         sodium channel, type IV, beta                               **−2.05**     **−2.33**   **−2.65**
  Slc16a6                                   solute carrier family 16 (monocarboxylic acid transporters), member 6           **−3.03**     **−3.20**   **−3.22**
  Slc17a7                                                    solute carrier family 17, member 7                               −1.94       **−2.95**     −1.20
  Slc1a5                                     solute carrier family 1 (neutral amino acid transporter), member 5             **−3.29**       −1.49       −1.85
  Slc22a3                                      solute carrier family 22 (organic cation transporter), member 3              **−2.31**     **−3.59**   **−3.39**
  Slc4a11                                       solute carrier family 4, sodium borate transporter, member 11                 −1.87       **−2.71**   **−3.68**
  Slc5a1                                      solute carrier family 5 (sodium/glucose cotransporter), member 1                −1.47         −2.07     **−2.57**
  Slc9a3r1                                solute carrier family 9 (sodium/hydrogen exchanger), member 3 regulator 1         **−1.92**     **−2.25**   **−2.21**
  *Metabolic process*                                                                                                                                
  Stard4                                           StAR-related lipid transfer (START) domain containing 4                    −1.37         −1.89     **−2.01**
  Pla1a                                                           phospholipase A1 member A                                   −2.07       **−2.77**   **−2.60**
  Agpat7                                                acylglycerol-3-phosphate O-acyltransferase 7                          −1.69       **−1.82**   **−1.85**
  Asah3l                                                   N-acylsphingosine amidohydrolase 3-like                            −1.30       **−2.03**   **−1.22**
  Hpse2                                                                 heparanase-2                                          −2.47         −2.35     **−3.27**
  Mtmr1                                                        myotubularin related protein 1                                  1.73         −1.42     **−5.07**
  Neu2                                                                 neuraminidase 2                                        −1.74       **−2.06**   **−2.08**
  *Neuropeptide/Hormone activity*                                                                                                                    
  Hcrtr1                                                       hypocretin (orexin) receptor 1                                 −2.61       **−2.64**     −2.27
  Nmu                                                                   neuromedin U                                        **−4.72**     **−7.99**   **−7.03**
  Tshr                                                      thyroid stimulating hormone receptor                              −1.28         −2.19     **−3.45**
  *Nucleotide synthesis*                                                                                                                             
  Atp8                                                            ATP synthase F0 subunit 8                                 **−4.45**       −1.07       −1.62
  Rrm2                                                           ribonucleotide reductase M2                                  −1.45         −1.68     **−2.26**
  *Protein binding*                                                                                                                                  
  Admr                                                         G protein-coupled receptor 182                               **−3.16**       −1.06       −1.53
  Cblb                                                Cbl proto-oncogene, E3 ubiquitin protein ligase B                       −1.69         −1.66     **−2.03**
  Fbf1                                                         Fas (TNFRSF6) binding factor 1                                 −1.31         −1.53     **−1.97**
  Fblim1                                                   filamin binding LIM protein 1 (Fblim1)                           **−4.50**     **−5.41**   **−3.55**
  Hr                                                                      hairless                                          **−1.99**     **−1.94**   **−2.41**
  Mtbp                                                Mdm2, p53 binding protein (mouse) binding protein                     **−3.53**     **−3.53**   **−2.77**
  Osbp2                                                          oxysterol binding protein 2                                  −1.28       **−4.17**     −1.49
  Pbk                                                                PDZ binding kinase                                       −1.90         −3.75     **−5.36**
  Pscdbp                                     pleckstrin homology, Sec7 and coiled-coil domains, binding protein             **−5.18**     **11.24**   **−26.12**
  S100a3                                                       S100 calcium binding protein A3                              **−2.47**     **−2.35**   **−2.71**
  S100a4                                                       S100 calcium-binding protein A4                                −1.88       **−1.82**   **−2.41**
  Serinc2                                                           serine incorporator 2                                     −2.87         −5.75     **−8.18**
  Tnni3                                                          troponin I type 3 (cardiac)                                **−2.52**     **−3.21**   **−5.57**
  Tpx2                                                      TPX2, microtubule-associated, homolog                           **−2.06**     **−3.81**   **−2.93**
  Ttr                                                                   transthyretin                                         −8.88       **−9.37**     11.99
  *Protein localization*                                                                                                                             
  Grik5                                                   glutamate receptor, ionotropic, kainate 5                           −2.58       **−2.13**     −2.03
  Grin2c                                                   glutamate receptor, ionotropic, NMDA2C                           **−2.00**     **−2.01**   **−2.52**
  Kdelr3                                  KDEL (Lys-Asp-Glu-Leu) endoplasmic reticulum protein retention receptor 3           −2.23       **−2.12**     −1.85
  Wnk4                                                      WNK lysine deficient protein kinase 4                             −1.34         −1.66     **−1.82**
  *Proteolysis*                                                                                                                                      
  Ace                                            angiotensin I converting enzyme (peptidyl-dipeptidase A) 1                 **−2.66**     **−2.90**   **−2.56**
  Adamts19                                       ADAM metallopeptidase with thrombospondin type 1 motif, 19                   −1.91       **−2.40**   **−4.19**
  Asb2                                                ankyrin repeat and SOCS box-containing protein 2                        −1.42       **−2.12**   **−2.53**
  Dusp14                                                       dual specificity phosphatase 14                                −1.38       **12.14**     −3.78
  Klk7                                                         kallikrein-related peptidase 7                                 −4.54       **−5.31**   **−8.54**
  Lct                                                                      lactase                                            −3.66       **−2.93**   **−3.80**
  Mcpt4l1                                                    mast cell protease 4-like 1provided                              −1.74         −1.72     **−1.92**
  Ppp1r1a                                         protein phosphatase 1, regulatory (inhibitor) subunit 1A                    −1.65       **−2.60**   **−2.41**
  Prss54                                                            protease, serine, 54                                    **−4.24**       −1.68       −2.33
  Sh3rf2                                                     SH3 domain containing ring finger 2                              −1.12       **−2.05**     −1.63
  *Regulation of nucleotide*                                                                                                                         
  Rap1gap2                                                    RAP1 GTPase activating protein 2                                −1.56         −3.02     **−2.80**
  *Sensory perception*                                                                                                                               
  Armc4                                                         armadillo repeat containing 4                                 −1.10         −1.24     **−2.52**
  Olr1260                                                          olfactory receptor 1260                                    −2.79         −2.31     **−3.10**
  Olr1579                                                          olfactory receptor 1579                                    −3.05         −3.33     **−3.90**
  Olr257                                                           olfactory receptor 257                                     −1.01       **−2.29**   **−2.44**
  Olr271                                                           olfactory receptor 271                                     −2.55         −1.70     **−3.10**
  Olr828                                                           olfactory receptor 828                                     −2.15       **−2.21**   **−2.21**
  Trpm8                                      transient receptor potential cation channel, subfamily M, member 8               −2.16       **−3.57**     −1.81
  *Signal transduction*                                                                                                                              
  Arhgap25                                                    Rho GTPase activating protein 25                              **−3.30**     **−3.23**   **−4.25**
  Arhgap9                                                      Rho GTPase activating protein 9                                −1.62         −2.18     **−2.44**
  Arhgef19                                             Rho guanine nucleotide exchange factor (GEF) 19                        −1.86       **−2.17**     −1.92
  Bcar3                                                   breast cancer anti-estrogen resistance 3                            −1.77       **−2.26**   **−2.04**
  Cacng1                                             calcium channel, voltage-dependent, gamma subunit 1                      −2.88       **−5.20**   **−7.25**
  Camk4                                                calcium/calmodulin-dependent protein kinase IV                         −1.37       **−1.87**   **−1.92**
  Cck                                                                  cholecystokinin                                        −1.68       **−3.43**     −1.96
  Cnr1                                                         cannabinoid receptor 1 (brain)                               **−2.17**     **−2.44**   **−2.38**
  Galnt14                            UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 14      −1.98       **−2.41**   **−2.17**
  Garnl4                                                      RAP1 GTPase activating protein 2                                −1.56       **−2.96**   **−2.80**
  Gpcr12                                                        G protein-coupled receptor 12                                 −1.55         −1.85     **−2.10**
  Madh7                                                                 MAD homolog 7                                         −1.71         −2.35     **−1.97**
  Mas1                                                                  MAS1 oncogene                                         −1.65         −2.69       −1.63
  Mrgprb2                                          MAS-related G protein-coupled receptor, member X2-like                   **−3.03**       −4.01       −3.45
  Nrgn                                                                   neurogranin                                          −1.64         −1.93     **−1.87**
  Nxph4                                                                neurexophilin 4                                        −1.46         −1.81     **−2.74**
  Rasd2                                                             RASD family, member 2                                     −1.75       **−2.10**   **−2.09**
  Rasgrp2                                                      RAS guanyl releasing protein 2                                 −1.62       **−1.95**   **−2.29**
  Rasl10a                                                       RAS-like, family 10, member A                               **−2.88**     **−2.57**   **−2.63**
  Syt5                                                                 synaptotagmin V                                        −1.10         −1.31     **−1.92**
  Tmem45b                                                         transmembrane protein 45b                                 **−9.59**     **−8.29**   **−6.92**
  Tmepai                                                transmembrane, prostate androgen induced RNA                          −2.04       **−2.59**   **−2.27**
  Vgf                                                         VGF nerve growth factor inducible                               −1.61       **−2.41**   **−2.37**
  *Spindle organization*                                                                                                                             
  Aspm                                             asp (abnormal spindle) homolog, microcephaly associated                    −1.68         −2.08     **−2.41**
  Kntc2                                                           kinetochore associated 2                                    −1.77         −1.72     **−3.10**
  Ndc80                                                 NDC80 homolog, kinetochore complex component                          −2.41         −2.41     **−1.39**
  Nusap1                                                 nucleolar and spindle associated protein 1                           −3.41       **−3.78**   **−3.78**
  *Structural*                                                                                                                                       
  Mospd4                                                      motile sperm domain containing 4                                −1.34         −1.58     **−2.12**
  Tspear                                            thrombospondin-type laminin G domain and EAR repeats                      −2.50         −1.81     **−4.08**
  *Transcription*                                                                                                                                    
  Ccdc77                                                      coiled-coil domain containing 77                              **−20.26**      −2.71     **−8.90**
  Ccer1                                                 Ccer1 -- coiled-coil glutamate-rich protein 1                       **−3.10**       −2.41       −1.39
  Ccna2                                                                   cyclin A2                                           −2.00       **−5.94**   **−8.77**
  Creb1                                                   cAMP responsive element binding protein 1                           −1.02       **−2.24**      1.06
  Ebf1                                                              early B-cell factor 1                                     −1.33         −1.77       −2.07
  Fst                                                                 follistatin (Fst)                                     **−2.06**     **−2.73**   **−2.24**
  Glrp1                                                          glutamine repeat protein 1                                   −1.74       **−3.28**     −2.14
  Hmgb2                                                           high mobility group box 2                                   −1.48       **−2.07**   **−2.14**
  Klf10                                                            Kruppel-like factor 10                                     −1.31       **−2.88**     −1.79
  Melk                                                    maternal embryonic leucine zipper kinase                            −1.98       **−2.00**     −1.90
  Nanog                                                                Nanog homeobox                                         −1.33       **−2.97**     −1.12
  Nr4a2                                                nuclear receptor subfamily 4, group A, member 2                        −1.20       **−2.80**     −1.21
  Ns5atp9                                             NS5A (hepatitis C virus) transactivated protein 9                       −1.89       **−4.35**   **−6.72**
  Onecut2                                                            one cut homeobox 2                                       −1.65         −1.95     **−2.25**
  Pdlim1                                                            PDZ and LIM domain 1                                      −2.14       **−2.62**   **−1.92**
  Rarres1                                                    retinoic acid receptor responder 1                             **−2.24**       −1.72       −1.26
  Rcor2                                                              REST corepressor 2                                       −2.21       **−3.39**     −2.31
  Rxrg                                                            retinoid X receptor gamma                                   −1.63       **−1.84**   **−2.06**
  Samd7                                                    sterile alpha motif domain containing 7                          **−3.19**       −1.61       −1.64
  Sfmbt2                                                      Scm-like with four mbt domains 2                                −1.84         −2.07     **−2.91**
  Tcf15                                                            transcription factor 15                                  **−1.82**     **−1.98**   **−2.15**
  Thrsp                                                      thyroid hormone responsive protein                               −1.60       **−2.20**     −1.63
  Timeless                                                        timeless circadian clock                                    −1.28         −1.68     **−1.95**
  Traf4af1                                                        TRAF4 associated factor 1                                   −2.53       **−8.01**   **−8.80**
  Ttn                                                                       titin                                             −1.91       **−2.28**   **−3.76**
  Ube2c                                                       ubiquitin-conjugating enzyme E2C                                −1.00       **−2.36**   **−2.42**
  *Unknown*                                                                                                                                          
  Linc00514                                              long intergenic non-protein coding RNA 514                         **−2.14**     **−2.72**   **−3.34**
  Lrrc10b                                                    leucine rich repeat containing 10B                             **−2.21**     **−3.29**   **−2.94**
  Edc4                                                          enhancer of mRNA decapping 4                                **−2.40**     **−2.73**   **−2.73**

The animals were treated and microarray analyses were performed as described in the text. The number listed in bold under the representative columns (SMvSS, MSvSS, MMvSS) identify genes whose mRNA were significantly increased according to the following criteria: lesser than −1.8-fold, p\<0.01. In some cases, values that are greater than −1.8-fold are not in bold because they did not reach the p value cut-off for the microarray analysis.

The classes of genes that are differentially expressed in the MMvSS comparison are described in [Table 2](#pone-0084665-t002){ref-type="table"}. That list includes *Avp* (15.99-fold), *Oxt* (14.91-fold), *Crh* (7.33-fold), and *Cart* (4.97-fold) that were upregulated. Several IEGs were also induced in that comparison. The genes affected in that group are involved in development and function of endocrine systems, cell signaling, and molecular transport. [Figure 4A](#pone-0084665-g004){ref-type="fig"} shows a network of genes involved in cell signaling and molecular transport whereas [figure 4B](#pone-0084665-g004){ref-type="fig"} shows a network that contains genes involved in development and endocrine functions. Canonical pathways affected by this treatment paradigm include cAMP-mediated signaling and CRH signaling. The potential role of some of these genes and pathways in METH-induced neuroadaptations is discussed below.

![An acute METH injection produces differential gene expression in METH-pretreated rats.\
This network of related genes was generated as described in [figure 2](#pone-0084665-g002){ref-type="fig"}. Relationships between genes are also described in [figure 2](#pone-0084665-g002){ref-type="fig"}. The rats were injected with METH (10 mg/kg) and were euthanized 2 hours after a second injection of METH (2.5 mg/kg) given one month later. The genes were from the MMvSS comparison shown in [figure 1](#pone-0084665-g001){ref-type="fig"}. (**A**) This network shows genes that participate in cell signaling and molecular transport. (**B**) Acute METH injection influences the expression of neuropeptides in METH-pretreated rats. Several transcripts including Avp, Cart, and Crh (CRF) showed upregulation after the second METH injection. Note some of the similarities between this network and the one shown in [figure 2](#pone-0084665-g002){ref-type="fig"}.](pone.0084665.g004){#pone-0084665-g004}

[Table 4](#pone-0084665-t004){ref-type="table"} shows some genes that were affected in the MMvMS comparison. These genes include *Npas4* (4.09-fold), *c-fos* (3.84-fold), *Nr4a3* (2.87-fold), *Arc* (2.09-fold), and *Crh* (1.83-fold) that were upregulated. These IEGs were also up-regulated in the SMvSS comparison but showed normal mRNA levels in the MS group. The fact that they are also significantly increased in the MMvSS and MMvMS comparison indicates that their responses to the second acute injection of METH were not significantly affected by the prior injection of the larger METH dose given one month earlier. This is in contrast to the observation for *Crh* that showed increased expression in the MS group, with a further potentiated response in the MMvMS comparison. Genes with altered gene expression participate in inflammatory responses, endocrine system disorders, cell signaling, and nervous system development. Canonical pathways included ERK/MAPK signaling and CRH signaling.

10.1371/journal.pone.0084665.t004

###### Partial list of METH-upregulated genes in the MMvMS comparison.

![](pone.0084665.t004){#pone-0084665-t004-4}

  Symbol                                            Definition                            Fold changes
  ----------------------- -------------------------------------------------------------- --------------
  *Cell adhesion*                                                                        
  Ptpn3                         protein tyrosine phosphatase, non-receptor type 3             2.54
  Ptpn4                         protein tyrosine phosphatase, non-receptor type 4             2.39
  *Cell migration*                                                                       
  Cd34                                             CD34 antigen                               5.27
  Nck1                      non-catalytic region of tyrosine kinase adaptor protein 1         2.77
  Sorl1                    sortilin-related receptor, L(DLR class) A repeats-containing       4.06
  *Development*                                                                          
  Col8a1                                 procollagen, type VIII, alpha 1                      6.41
  *Hormone activity*                                                                     
  Crh                                    corticotropin releasing hormone                      1.83
  F5                                           coagulation factor 5                          24.26
  Igfbp2                           insulin-like growth factor binding protein 2               2.16
  Lhb                             luteinizing hormone beta, transcript variant 2              1.82
  Porf1                                    preoptic regulatory factor 1                       1.94
  Prok2                                           prokineticin 2                              2.97
  Scgb1c1                               secretoglobin, family 1C, member 1                    6.95
  Sostdc1                                 sclerostin domain containing 1                     30.53
  Ttr                                             transthyretin                              112.39
  *Immune response*                                                                      
  Bpil1                        bactericidal/permeability-increasing protein-like 1            3.12
  Nfil3                              nuclear factor, interleukin 3 regulated                  2.01
  *Ion binding*                                                                          
  Arid5a                                  AT rich interactive domain 5A                       7.56
  *Ion transport*                                                                        
  Kcnh7                            potassium voltage-gated channel, subfamily H               3.75
  Kcnt2                              potassium channel, subfamily T, member 2                 2.11
  Slco1a5                  solute carrier organic anion transporter family, member 1a5        4.00
  Steap1                      six transmembrane epithelial antigen of the prostate 1          6.18
  *Metabolic process*                                                                    
  Asah2                                 N-acylsphingosine amidohydrolase 2                    3.54
  Glb1l3                                   galactosidase, beta 1-like 3                       3.03
  Mtmr1                                   myotubularin related protein 1                      4.40
  *Protein binding*                                                                      
  Eif3s12                     eukaryotic translation initiation factor 3, subunit 12          2.00
  Kpna4                                   karyopherin (importin) alpha 4                      1.82
  *Protein transport*                                                                    
  Nup133                                         nucleoporin 133                              2.33
  *Proteolysis*                                                                          
  Dusp1                                   dual specificity phosphatase 1                      1.88
  Dusp4                                   dual specificity phosphatase 4                      3.80
  Ppp1r15b                        protein phosphatase 1, regulatory subunit 15b               1.99
  Usp31                                   ubiquitin specific protease 31                      2.91
  *Sensory perception*                                                                   
  Mfrp                       membrane frizzled-related protein, transcript variant 1         14.56
  *Signal transduction*                                                                  
  Adcy6                                        adenylate cyclase 6                            3.28
  Arc                           activity regulated cytoskeletal-associated protein            2.09
  Lhfpl4                            lipoma HMGIC fusion partner-like protein 4                2.66
  Manba                                   mannosidase, beta A, lysosomal                      2.39
  Pank3                                       pantothenate kinase 3                           1.85
  Plac9                                        placenta-specific 9                            4.06
  Rab33b                              RAB33B, member of RAS oncogene family                   4.18
  *Transcription*                                                                        
  Bmp7                                     bone morphogenetic protein 7                       1.81
  Egr4                                       early growth response 4                          2.05
  Fos                             FBJ murine osteosarcoma viral oncogene homolog              3.84
  Msc                                                musculin                                 6.35
  Npas4                                   neuronal PAS domain protein 4                       4.09
  Nr1i3                          nuclear receptor subfamily 1, group I, member 3              2.61
  Nr2c2                          nuclear receptor subfamily 2, group C, member 2              2.78
  Nr4a2                          nuclear receptor subfamily 4, group A, member 2              2.32
  Nr4a3                          nuclear receptor subfamily 4, group A, member 3              2.87

The animals were treated and microarray analyses were performed as described in the text. The gene list was generated based on the following criteria: greater than +1.8-fold, p\<0.01. The genes within each class are listed in descending order based on fold-changes in MMvMS comparison.

Quantitative PCR analysis {#s2c}
-------------------------

We used qPCR to confirm the changes in gene expression of some genes of interest. [Figure 4](#pone-0084665-g004){ref-type="fig"} shows METH-induced changes in mRNA levels for *Crh* and its receptors (4 rats in SS; 6 rats in SM; 7 rats in each MS and MM groups respectively). A single injection of METH (2.5 mg/kg) caused significant increases (5.7-fold) in *Crh* mRNA levels ([Fig. 5A](#pone-0084665-g005){ref-type="fig"}) in saline-pretreated rats (SMvSS). Similar increases (6.0-fold) were observed in rats that had been injected with an injection of METH (10 mg/kg) a month earlier (MSvSS). As per the array data, the injection of the smaller METH dose caused further increases (11.6-fold) in *Crh* expression in rats pretreated with METH (10 mg/kg dose) a month earlier, with increases in the MMvSS comparison being significantly higher than in the SMvSS and MSvSS comparisons ([Fig. 5A](#pone-0084665-g005){ref-type="fig"}). We also measured the expression of CRH receptors after the METH injections. Acute METH caused significant increases *Crhr1* mRNA levels in saline-pretreated (1.8-fold, SMvSS) and in METH-pretreated (1.8-fold, MMvSS) rats ([Fig. 5B](#pone-0084665-g005){ref-type="fig"}). There were also increases (2.2-fold) in the animals that had received the larger METH dose a month earlier (MSvSS, [Fig. 5B](#pone-0084665-g005){ref-type="fig"}). Interestingly, we observed significant greater increases in *Crhr2* mRNA expression in the SMvSS (∼5-fold), MSvSS (4.5-fold), and MMvSS (6.5-fold) comparisons ([Fig. 5C](#pone-0084665-g005){ref-type="fig"}) than those observed for *Crhr1* expression (compare [Fig. 5B to 5C](#pone-0084665-g005){ref-type="fig"}).

![METH induced changes in the expression of neuropeptides in the rat NAc.\
The figure shows the acute and more delayed effects of METH injections on the mRNA levels of (**A**) CRH, (**B**) CRHR1, and (**C**) CRHR2. The PCR data confirmed the changes in expression in CRH expression observed in the microarray data and document changes in CRH receptor expression. Rats were injected (4 rats in SS; 6 rats in SM; 7 rats in each MS and MM groups respectively) and total RNA was extracted from the NAc as described in the text. Statistical significance was determined by ANOVA followed by post-hoc tests. The null hypothesis was rejected at *P*\<0.05. Key to statistics: \* = *P*\<0.05, \*\* = *P*\<0.01; \*\*\* = *P*\<0.001, in comparison to the SS group; \#\#\# = *P*\<0.001, in comparison to the SM group; !!! = *P*\<0.001, in comparison to the MS group.](pone.0084665.g005){#pone-0084665-g005}

[Figure 6A](#pone-0084665-g006){ref-type="fig"} shows that there were increased Avp mRNA expression in the SMvSS (7.2-fold), the MSvSS (3-fold), and MMvSS (3.5-fold) comparisons. METH injections also caused increased oxytocin expression in SMvSS (3.9-fold), MSvSS (5.3-fold) and MMvSS (3.7-fold) ([Fig. 6B](#pone-0084665-g006){ref-type="fig"}). The single METH (10 mg/kg), given one month earlier caused greater changes in *Cart* expression in the MSvSS (8.8-fold) comparison than those observed in the SMvSS (6.2-fold) and MMvSS (4.7-fold) ([Fig. 6C](#pone-0084665-g006){ref-type="fig"}) comparisons. [Figure 6D](#pone-0084665-g006){ref-type="fig"} shows the effects of METH on *Gnrh1* expression. As per the array data, acute METH increased GnRH1 in the SMvSS (5.4-fold) and MMvSS (7.7-fold) comparisons. The single injection of the larger METH dose also caused long-lasting changes in *Gnrh1* expression in the MS (6.3-fold) group. The changes in *Gnrh1* expression in the MMvSS comparison were significantly higher than those observed in the SMvSS, suggesting that the previous METH injection had enhanced the effects of the second METH injection. Importantly, a correlation analysis revealed a significant positive correlation (*r* = 0.70, *p* = 0.000006) between the microarray and qPCR data ([Fig. 7](#pone-0084665-g007){ref-type="fig"}).

![METH induced changes in the expression of neuropeptides in the rat NAc.\
The figure shows the acute and more delayed effects of METH injections on the mRNA levels of (**A**) Vasopressin, (**B**) Oxytocin, (**C**) CART, and (**D**) GnRH1 measured by quantitative PCR. The PCR data confirmed the microarray data. Key to statistics: \* = *P*\<0.05, \*\* = *P*\<0.01; \*\*\* = *P*\<0.001, in comparison to the SS group; \# = *P*\<0.05; \#\# = *P*\<0.01; \#\#\# = *P*\<0.001, in comparison to the SM group; !!! = *P*\<0.001, in comparison to the MS group.](pone.0084665.g006){#pone-0084665-g006}

![qPCR validation of METH-induced changes identified by microarray analysis.\
There is a significant correlation between METH-induced changes in the expression of genes identified by microarray analysis and validated by qRT-PCR.](pone.0084665.g007){#pone-0084665-g007}

Discussion {#s3}
==========

The present study shows that an acute METH (2.5 mg/kg) injection can cause differential changes in gene expression in the rat NAc. The transcriptional profiles observed after the METH injections indicate that METH can induce the expression of several genes that participate in the control of transcription and cAMP signaling in the NAc. These findings are consistent with the fact that METH exerts its effects, in part, by releasing DA followed by stimulation of DA D1 receptors that are linked to cAMP activation [@pone.0084665-Jayanthi1], [@pone.0084665-Cadet3]. In fact, use of the DA antagonist, SCH23390, produces substantial inhibition of the acute transcriptional effects of METH [@pone.0084665-Jayanthi1], [@pone.0084665-Cadet3]. We also show, for the first time, that a moderate dose of METH (10 mg/kg) can have long-lasting effects on gene expression in the NAc. Pre-exposure to this METH dose influenced METH-induced changes in the expression of many genes upon re-exposure of the rats to a smaller METH dose given a month later. For example, prior exposure to METH led to the potentiation of increased *Crh* mRNA expression induced by a second METH injection. Taken together, these METH-induced alterations in gene expression in the NAc support the notion that METH can exert pleiotropic effects in the brain [@pone.0084665-Cadet1], [@pone.0084665-Jayanthi1]--[@pone.0084665-Jayanthi2]. This conclusion is consistent with results of the pathway analyses that identified METH-induced changes in canonical pathways related to cell-to-cell communication, endocrine functions, and inflammatory responses. The identification of these pathways is of interest and adds to the literature that suggests addiction to psychostimulant involves perturbations in synaptic pathology in a number of neurotransmitter systems [@pone.0084665-Mameli1], resulting, in part, from drug-induced transcriptional changes in the brain [@pone.0084665-Maze1], [@pone.0084665-Nestler1].

Although drug-induced sensitization has been studied mostly in models where repeated injections of psychostimulant are given [@pone.0084665-Steketee1], considerable evidence exists to suggest that a single injection of drugs of abuse can cause long-term neurochemical, neuroendocrine, and physiological effects in rodents. For example, enhanced amphetamine-induced striatal DA release was reported after a single injection of either amphetamine [@pone.0084665-Robinson1] or cocaine [@pone.0084665-Peris1]. A single cocaine injection enhanced NAc DA release in response to a second cocaine injection given a week later [@pone.0084665-Keller1]. A single in vivo exposure to cocaine can cause prolonged long-term potentiation in NAc neurons [@pone.0084665-Ungless1] [@pone.0084665-Krasnova2]. A single higher dose of cocaine (20 mg/kg) also enhanced the response to a second dose of cocaine (10 mg/kg) and enhanced the expression *GluR1* and *GAP-43* mRNA in the NAc [@pone.0084665-Grignaschi1]. Similar observations have been reported in response to a two-injection pattern of amphetamine administration [@pone.0084665-Vanderschuren1] in a paper that uses a paradigm similar to the METH injection schedule used in the present study. These authors reported enhanced biochemical effects of a second amphetamine (1 mg/kg) injection after prior exposure to the drug (5 mg/kg) [@pone.0084665-Vanderschuren1]. Together, these reports are consistent with our finding that the prior injection of a moderate dose of METH (10 mg/kg) caused enhancement of the increased *Crh* mRNA expression induced by the administration of a lower METH dose (2.5 mg/kg). CRH/CRF is a 41 amino acid peptide that was identified as a hypothalamic releasing factor that stimulated the secretion of adrenocorticotropic hormone (ACTH) and beta-endorphin [@pone.0084665-Vale1], and of corticosterone [@pone.0084665-Rivier1]. Subsequent studies also demonstrated that CRH [@pone.0084665-Cummings1]--[@pone.0084665-Merchenthaler1] and CRH receptor proteins and mRNAs [@pone.0084665-DeSouza1]--[@pone.0084665-VanPett1] are widely distributed in the central nervous system (CNS).

These observations suggest that CRH and its receptors might serve to integrate physiological responses to stressful stimuli [@pone.0084665-Bale1]--[@pone.0084665-McEwen1]. Our findings that METH can cause increased mRNA expression of *Crh* and of its receptors (*Crfr1/Crhr1 and Crfr2/Crhr2*) are consistent with reports that both *Crh* and *Crhr1* mRNA levels are increased by stress [@pone.0084665-Makino1]--[@pone.0084665-RabadanDiehl1] and by intracerebral administration of CRH itself [@pone.0084665-Imaki1], [@pone.0084665-Mansi1]. Our results are also consistent with previous data that had implicated the CRH system in METH-induced locomotor effects [@pone.0084665-Giardino1], [@pone.0084665-Giardino2]. Our data are also in line with the reported activation of the hypothalamic-pituitary-adrenal (HPA) axis by various drugs of abuse [@pone.0084665-Armario1]. Our observations of METH-induced *Crhr1* and *Crhr2* expression are also consistent with a previous report that *Crhr1* gene expression in limbic brain regions is important to neuroendocrine responses to stress [@pone.0084665-Muller1] and with the fact that *Crhr2*-mutant mice are more sensitive to stress [@pone.0084665-Bale2]. Interestingly, we found that METH caused greater increases in *Crhr2* than in *Crhr1* expression in all three groups of METH-treated rats. These observations are consistent with those of other investigators who had reported differential responses in *Crhr1* and *Crhr2* expression associated with stress, with CRHR1 being internalized and CRHR2 being recruited to the cell membrane [@pone.0084665-Waselus1], [@pone.0084665-Wood1]. They are also consistent with reports that chronic cocaine facilitates the electrophysiological effects of CRHR2 stimulation [@pone.0084665-Liu1], [@pone.0084665-OrozcoCabal1]. Importantly, our observations of METH-induced increased *Crh* and *Crhr* mRNA expression are in agreement with previous results that a single injection of amphetamine (1 mg/kg) induced time-dependent sensitization of the HPA axis such that, by 1--3 weeks after a prior injection of amphetamine (5 mg/kg), there was an augmented secretion of ACTH and corticosterone consequent to a second injection of amphetamine (1 mg/kg) [@pone.0084665-Vanderschuren1]. When taken together with previous findings, the present observations add more support to the accumulating evidence that disturbances in CNS stress response systems might play an important role in long-term molecular adaptations consequent to psychostimulant exposure [@pone.0084665-Koob1]. Our findings might also be relevant to stress- and drug-induced reinstatement of drug taking, with differential involvement of various limbs of these neuroendocrine cascades being more or less involved in certain aspects of addictive behaviors [@pone.0084665-Le1], [@pone.0084665-Shalev1]. Together with our observations of METH-induced greater changes in *Crhr2* than in *Crhr1* expression, the reviewed literature implicates both CRH receptors in the behavioral and physiological effects of psychostimulant, with CRHR2 playing a more prominent role that it had been assigned so far [@pone.0084665-Gysling1].

We found that the METH (10 mg/kg) injection caused long-lasting increases in *Avp* mRNA levels. Arginine vasopressin (AVP), one of the first identified neuropeptides, is found predominantly in the hypothalamus [@pone.0084665-Swaab1]. AVP is located in other brain regions including the NAc [@pone.0084665-RodriguezBorrero1] where it interacts with specific AVP receptors [@pone.0084665-Koshimizu1], [@pone.0084665-Peter1]. AVP also interacts with the HPA axis, the extended amygdala, and monoaminergic systems [@pone.0084665-Locatelli1]. AVP is co-regulated with CRH [@pone.0084665-Makino2] and AVP-expressing hypothalamic neurons co-express CRHR1 and CRHR2 receptors [@pone.0084665-Arima1], results that support the co-involvement of CRH and AVP in stress responses [@pone.0084665-Aguilera1], [@pone.0084665-Caldwell1]. This discussion is consistent with the pathway analysis that shows a direct interaction of AVP and CRH ([Fig. 2](#pone-0084665-g002){ref-type="fig"}). Interestingly, the IPA also shows that both peptides are linked to the expression of the IEGs, *c-fos* and *Creb*, whose mRNAs are also induced by the acute METH injection ([Fig. 2](#pone-0084665-g002){ref-type="fig"}). Moreover, our findings of increased *Avp* mRNA expression are consistent with reports that administration of another stimulant, cocaine, can increase *Avp* mRNA in the NAc [@pone.0084665-RodriguezBorrero1]. *Avp* mRNA is increased within 3 hours after cessation of chronic cocaine administration (3×15 mg/kg per day for 14 days) [@pone.0084665-Zhou1] and the increased mRNA expression persists for several weeks during protracted withdrawal from escalating-dose cocaine administration [@pone.0084665-Zhou2]. In addition to the effects of cocaine, stimulation of the mesolimbic system by local injection of a substance P analog into the ventral tegmental area also induces AVP release [@pone.0084665-Cornish2], [@pone.0084665-Cornish3], indicating that this neuropeptide might indeed be an important mediator of some of the physiological effects of psychostimulant since these drugs exert their varied effects through stimulation of monoaminergic systems [@pone.0084665-Bustamante1]--[@pone.0084665-Xi1]. This suggestion is consistent with the demonstration that AVP and its analogues can reduce cocaine self-administration in rats [@pone.0084665-deVry1], [@pone.0084665-vanRee1]. Taken together with cocaine administration results, our observation of METH-induced prolonged increases in *Avp* mRNA levels supports the notion that AVP might also participate in neuroadaptive responses triggered by repeated exposure to psychostimulants.

CART is another peptide whose mRNA expression was induced in the different groups of METH-injected rats. CART is a neuropeptide that was discovered using PCR differential display as a rat brain mRNA that responded to cocaine and amphetamine [@pone.0084665-Douglass1], [@pone.0084665-Douglass2]. CART is distributed throughout the brain [@pone.0084665-Douglass2] and is thought to be relevant to the effects of psychostimulants on the reward system in the brain [@pone.0084665-Kuhar1], [@pone.0084665-Fagergren1]--[@pone.0084665-Rogge1]. CART also participates in stress responses [@pone.0084665-Balkan1], [@pone.0084665-Dominguez1]. Of considerable interest to our present observations is the report that CART can activate the HPA axis through a CRH receptor-dependent mechanism [@pone.0084665-Smith1]. Thus, together with the observed changes in *Crh* and *Avp* mRNA expression after the METH injections, the METH-induced increased *Cart* mRNA expression suggests that METH can cause coordinated changes in the expression of neuropeptides that modulate stress responses in the brain. Similar observations have been made in response to other stressful events [@pone.0084665-Herman1], [@pone.0084665-Jankord1].

The acute and prolonged changes in *Oxt* expression caused by METH are also of singular interest. Oxytocin (Oxt) is a nanopeptide [@pone.0084665-DuVigneaud1] that is involved in affiliative [@pone.0084665-Insel1], grooming [@pone.0084665-Drago1], maternal [@pone.0084665-Shahrokh1], pair bonding [@pone.0084665-Liu2], and other complex behaviors [@pone.0084665-Burkett1]--[@pone.0084665-Neumann1]. Our observations of METH-induced changes in *Oxt* expression are consistent with those of several studies that have now reported the potential involvement of Oxt in the behavioral and biochemical effects of psychostimulants [@pone.0084665-Carson1], [@pone.0084665-McGregor1]. For example, it has been reported that Oxt is itself rewarding when tested in the conditioned place preference (CPP) paradigm [@pone.0084665-Liberzon1]. In contrast, Oxt reduced cocaine-induced hyperactivity [@pone.0084665-Kovacs1], stereotypy [@pone.0084665-Sarnyai1], and self-administration [@pone.0084665-Sarnyai2]. More recent studies have provided evidence that Oxt can decrease METH-induced hyperactivity [@pone.0084665-Qi1], CPP [@pone.0084665-Baracz1], [@pone.0084665-Qi2], METH self-administration [@pone.0084665-Carson2], and relapse to METH-seeking behaviors [@pone.0084665-Carson2], [@pone.0084665-Cox1]. Oxt also decreased METH-induced activation of the subthalamus nucleus and of the NAc core [@pone.0084665-Carson3]. Although not yet completely elucidated, these effects of Oxt on METH-induced behaviors are probably due, in part, to its effects on the dopaminergic systems since Oxt can reduce METH-induced DA release in the NAc [@pone.0084665-Qi1] and serve as a neuromodulator of dopaminergic functions in various behavioral models [@pone.0084665-Baskerville1], [@pone.0084665-Skuse1]. When taken together with our present findings, the reviewed literature supports the idea that more studies of this important neuromodulatory system are warranted in models of drug addiction [@pone.0084665-McGregor1]. In view of the observed effects of METH on both Oxt and Avp expression, it will be important to dissect the specific role of each peptide in drug addiction because they are both involved in the modulation of various mammalian behaviors [@pone.0084665-Shahrokh1], [@pone.0084665-Donaldson1], [@pone.0084665-MeyerLindenberg1].

In summary, this is the first demonstration that a single injection of a moderate METH dose can cause long-lasting alterations in gene expression in the NAc. These changes include prolonged overexpression of mRNAs that code for several neuropeptides including AVP, CART CRH, CART, and OXT that are involved in multipronged neuroendocrine responses to environmental stimuli stress and affiliative interactions. The augmented responses in CRH transcript expression suggest that the peptide might also play important roles in the molecular events that drive plastic alterations in the NAc in response to METH exposure, in a fashion consistent with stress-induced dynamic changes in the brain [@pone.0084665-McEwen1]. More studies are needed to further dissect the role of these neuropeptides in molecular neuroadaptations that are consequent to repeated drug exposure. The impact of these changes within specific cell types within the NAc core and shell subregions will also need to be elucidated.

Materials and Methods {#s4}
=====================

Animals, drug treatment, and tissue collection {#s4a}
----------------------------------------------

Male Sprague-Dawley rats (Charles River Labs, Raleigh, NC, USA), weighing 375±25 g, were used in the experiments. Rats were housed in a temperature-controlled (22.2+0.2°C) room with free access to food and water. All animals were allowed to acclimate to the facility for one week. At first, the animals received a single injection of either saline or METH (10 mg/kg). This injection was followed after a month delay by a second injection of either saline or METH (2.5 mg/kg). This pattern of injections yielded four groups of rats: saline-pretreated and saline-challenged (SS); saline-pretreated and METH-challenged (SM); METH-pretreated and saline-challenged (MS) and METH-pretreated and METH-challenged (MM), summarized in Figure S1 in [File S1](#pone.0084665.s001){ref-type="supplementary-material"}. Proper handling techniques were used to reduce stress to the animals during injections. Rats were euthanized at 2 hours after the second injection of either METH or saline. NAc tissues were dissected and immediately frozen on dry ice. The pattern of using a larger dose of METH followed by a second lower dose is consistent with studies in which single doses of either cocaine [@pone.0084665-Kalivas1] or amphetamine [@pone.0084665-Vanderschuren1] have been used to investigate biochemical sensitization to a second lower dose. Similarly, lower challenge doses of psychostimulants are used when measuring biochemical sensitization after repeated intermittent injections of increasing doses of either cocaine or amphetamine (see [@pone.0084665-Paulson1], [@pone.0084665-Robinson2] and references therein).

Initially, the brain was placed on its dorsal surface on a metal plate that was kept cold on crushed ice. The nucleus accumbens (containing both core+shell subregions) was dissected from the ventral surface of the brain. A wedge of brain tissue is obtained by cutting along two lines: one extending from the base of the lateral ventricle, through the anterior commissure to the medial edge of the lateral olfactory tract and the other connecting the base of the lateral ventricle and the base of the brain.

The tissues were kept at −70°C until they were processed for HPLC analysis or RNA extraction. All animal use procedures were according to the NIH Guide for the Care and Use of Laboratory Animals and were approved by the National Institute of Drug Abuse-/Intramural Research Program (IRP) Animal Care and Use Committee (NIDA/IRP-ACUC).

HPLC Analysis {#s4b}
-------------

Monoamine levels in the NAc were quantified by HPLC with electrochemical detection as described in our previous publications [@pone.0084665-Cadet2].

Briefly, NAc was homogenized in 0.01 M HClO~4~ and centrifuged at 14, 000×g for 15 min. DA, DOPAC, HVA, 5-HT, and 5-HIAA levels were measured by HPLC with electrochemical detection. The analytical column was SunFire C18 (5 µm particle size, 4.6×150.0 mm) from Waters (Waters Corp., Millford, MA). The mobile phase was 0.01 M sodium dihydrogenphosphate, 0.01 M citric acid, 2 mM sodium EDTA, 1 mM sodium octylsulfate, 10% methanol, pH 3.5 at flow rate 1.0 ml/min and temperature 35°C. The installation consisted of Waters 1525 Binary HPLC pump and Esa Coulochem III electrochemical detector (Thermo Fisher Scientific, Sunnyvale, CA). The glassy carbon electrode was used at a potential of 0.75 V. Peak areas and sample concentrations were calculated with the proprietary software program, Breezes (Waters Corp.). The program was used to calculate peak height and to integrate known standards for the HPLC data. Contents of DA, DOPAC and HVA were calculated as pg/mg of tissue weight.

RNA extraction, microarray hybridization, and data analysis {#s4c}
-----------------------------------------------------------

Total RNA was isolated according to the manufacturer\'s manual using Qiagen RNeasy mini kit (Qiagen, Valencia, CA, USA). RNA integrity was detected using an Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA) and showed no degradation (see Table S1 in [File S1](#pone.0084665.s001){ref-type="supplementary-material"} for details). Microarray hybridization was carried out using RatRef-12 Expression BeadChips arrays (22,523 probes) (Illumina Inc., San Diego, CA) essentially as previously described by our laboratory [@pone.0084665-Cadet2], [@pone.0084665-Martin1]. Briefly, a 600 ng aliquot of total RNA from each NAc sample was amplified using Illumina RNA Amplification kit (Ambion, Austin, TX). Single-stranded RNA (cRNA) was generated and labeled by incorporating biotin-16-UTP (Roche Diagnostics, Indianapolis, IN). 750 ng of each cRNA sample were hybridized to Illumina arrays at 55°C overnight according to the Whole-Genome Gene Expression Protocol for BeadStation (Illumina Inc.). Hybridized biotinylated cRNA was detected with Cyanine3-streptavidin (GE Healthcare, Piscataway, NJ) and quantified using Illumina\'s BeadStation 500GX Genetic Analysis Systems scanner. The Illumina BeadStudio software was used to measure fluorescent hybridization signals and to subtract the background signal. Background subtracted data was imported into GeneSpring software v.12 (Agilent Technologies) and baseline normalization to the median values of each array (n = 24) were performed. The normalized data were used to identify changes in gene expression after the injection of METH. A gene was identified as significantly changed if it showed increased or decreased expression according to an arbitrary cut-off of 1.8-fold changes at *P*\<0.01 using unpaired t-test in the GeneSpring statistical package. Similar criteria have been used successfully in our other studies [@pone.0084665-Cadet2], [@pone.0084665-Martin1]. The results are reported as fold changes calculated as the ratios of normalized gene expression data for METH-treated groups (SM, MS, and MM) in comparison to the control group (SS).

Quantitative polymerase chain reaction (qPCR) {#s4d}
---------------------------------------------

A portion of the total RNA (0.5 µg) isolated from the NAc samples used in the microarray analysis (Table S1 in [File S1](#pone.0084665.s001){ref-type="supplementary-material"}) was reverse-transcribed with oligo dT primers using Advantage RT-for-PCR kit (Clontech, Mountain View, CA). qRT-PCR was performed as described previously [@pone.0084665-Cadet2], [@pone.0084665-Martin1] with Roche LightCycler 480 II (Roche Diagnostics Corp., Indianapolis, IN) using iQ SYBR Green supermix (Bio-Rad, Hercules, CA). For all qRT-PCR experiments, individual data were normalized using the corresponding OAZ1 (ornithine decarboxylase antizyme 1) mRNA level. OAZ1 was used because its expression did not show any significant changes at any time points after the METH injection. The results are reported as fold changes calculated as the ratios of normalized gene expression data for METH-treated groups (SM, MS, and MM) in comparison to the control group (SS). The primers for RT-PCR were synthesized at the Synthesis and Sequencing Facility of Johns Hopkins University (Baltimore, MD, see Table S2 in [File S1](#pone.0084665.s001){ref-type="supplementary-material"}).

Statistical Analyses {#s4e}
--------------------

All data are presented as means ± SEM. Statistical analyses were performed using one-way ANOVA analysis followed by Fisher\'s protected least significant difference (StatView 4.02, SAS Institute, Cary, NC). The null hypothesis was rejected at p≤0.05.

Supporting Information {#s5}
======================

###### 

**Figure S1, Pictogram showing the drug treatment schedule.Table S1, RNA Integrity Number (RIN) of Samples. Table S2, List of RT-PCR primers.**

(DOCX)

###### 

Click here for additional data file.
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